German and international studies on SARS-CoV-2 seroprevalence

J Health Monit. 2020 Nov 13;5(Suppl 4):2-15. doi: 10.25646/7024. eCollection 2020 Nov.

Abstract

Since the beginning of the year 2020, the SARS-CoV-2 coronavirus has spread globally at a tremendous pace. Studies on the prevalence of SARS-CoV-2 antibodies in the population help estimate the number of people that have already been infected. They also allow an estimate of the number of undetected infections i.e. infections that do not appear in data on officially reported cases. The interpretation of study results needs to consider bias from selective sampling and the diagnostic test properties. To promote networking and co-operation between scientists, the Robert Koch Institute has compiled an overview of the seroepidemiological studies conducted in Germany on its website, which is regularly updated. The RKI conducts searches, for example of press releases, study registry entries or preprint server publications, and contacts the lead investigators of these studies. Of the 40 studies contacted so far, 24 have already provided information (as of 25.06.2020). We can differentiate between studies of the general population, of selected population groups such as healthcare workers, or of ongoing cohorts. This article provides an overview of such studies from Germany, but also of selected international studies. A special focus is set on studies of children and adolescents, which are now of particular interest due to the planned reopening of childcare facilities and schools.

Keywords: ANTIBODIES; INFECTIOUS DISEASE EPIDEMIOLOGY; SARS-COV-2; SEROEPIDEMIOLOGICAL STUDIES; SEROPREVALENCE.

Grants and funding

The development of the website on seroepidemiological studies in Germany and this manuscript were financed by the Robert Koch Institute.